Importantly, tumor vascular endothelial cells have been identified as a major source of type 1 interferon production in the TME following intratumoral injection of 2′3′-cGAMP-based STING agonists, which promote T-cell-mediated therapeutic antitumor immunity (15). Here, STING1 is linked to neoplasm.